July 2025 in “Journal of Investigative Dermatology” Upadacitinib effectively treats pyoderma gangrenosum.
474 citations
,
January 2012 in “Chemistry & biology” Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.
11 citations
,
January 1984 in “Veterinary Pathology” 4 citations
,
November 2024 in “Toxicology Research” Curcumin and piperine together may help protect lungs from paraquat damage.
39 citations
,
August 2022 in “Pharmaceutics” Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.
June 2023 in “Journal of Burn Care & Research” Using both bone marrow concentrate and platelet-rich plasma together improves skin wound healing in mice.
1 citations
,
September 2022 in “Canadian Journal of Ophthalmology” Paraproteinemic keratopathy can show eye symptoms before other signs of disease, needing careful treatment and long-term follow-up.
2 citations
,
January 2013 in “Iraqi journal of Medical Sciences” 7 citations
,
March 2023 in “Lasers in Surgery and Medicine” Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.
Encapsulating ascorbyl palmitate in curcumin-grafted particles improves its stability and skin penetration.
February 2022 in “Authorea (Authorea)” PAON shows skin patterns due to genetic mosaicism.
2 citations
,
October 2023 in “Skin Health and Disease” Alopecia neoplastica is hair loss from breast cancer spreading to the scalp.
14 citations
,
August 2024 in “BMC Pregnancy and Childbirth” Platelet-rich plasma can help thicken the endometrium and improve pregnancy rates.
April 2025 in “Frontiers in Pharmacology” Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
69 citations
,
February 2021 in “PLoS Computational Biology” Securinine and ajmaline may effectively treat liver cancer, with securinine being less toxic to normal cells.
24 citations
,
December 2011 in “International Journal of Cancer” PTH-CBD agonists may help regrow hair after chemotherapy.
61 citations
,
September 1994 in “Journal of Medical Genetics” Pachyonychia congenita is linked to a keratin gene on chromosome 17.
44 citations
,
June 2017 in “The EMBO Journal” LPA3 signaling in the uterus is crucial for placental formation and fetal development.
Vinblastine and its metabolites may cause nausea and hair loss by binding to specific receptors and could lead to better chemotherapy drugs with fewer side effects.
1 citations
,
August 1983 in “PubMed” CVP therapy showed moderate success in treating advanced non-Hodgkin's lymphoma, but more intensive treatment is needed for better outcomes.
10 citations
,
December 2008 in “Molecular Carcinogenesis” The PML protein helps prevent skin cancer in mice.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical gabapentin was safe and effective for treating scalp symptoms and promoting hair regrowth in cicatricial alopecias.
6 citations
,
September 2024 in “Current Oncology” Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.
1 citations
,
November 2023 in “Journal of Spinal Cord Medicine” IT PEP may help recovery after spinal cord injury, but more research is needed.
15 citations
,
January 2014 in “Medicinal chemistry” Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.
January 2005 in “Duo Research Archive (University of Oslo)” Metformin reduces pregnancy complications in women with PCOS.
May 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” A rare scalp tumor was removed from a 49-year-old woman, with a good outlook if benign but needing careful monitoring if malignant.
Spiny keratoderma is a rare skin condition with small spines on palms and soles, possibly linked to abnormal hair formation.
76 citations
,
August 2007 in “Supportive care in cancer” Chemotherapy often causes skin, nail, and hair side effects, significantly impacting quality of life.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.